📊 XBIO Key Takeaways
Is Xenetic Biosciences, Inc. (XBIO) a Good Investment?
Xenetic Biosciences exhibits severe fundamental deterioration despite superficially strong revenue growth. Zero gross profit on $3M revenue indicates the business model is not generating profitability at the product level, while negative operating cash flow of -$2.3M creates unsustainable cash burn with limited runway. The company requires either dramatic expense reduction, profitable revenue generation, or external financing to avoid cash depletion within 3-4 periods.
Why Buy Xenetic Biosciences, Inc. Stock? XBIO Key Strengths
- Exceptional liquidity with 8.32x current ratio and $7.9M cash position enabling short-term obligations
- Minimal leverage with 0.03x debt-to-equity and only $212.8K long-term debt reducing bankruptcy risk
- Revenue grew 1911% YoY indicating potential product traction or new revenue streams
XBIO Stock Risks: Xenetic Biosciences, Inc. Investment Risks
- Zero gross profit on $3M revenue signals fundamental unit economics failure or one-time revenue event with no scalability
- Operating cash burn of -$2.3M annually with only ~$7.9M cash creates 3-4 period runway to insolvency
- Operating margin of -95.2% and net margin of -90.1% demonstrate company loses $0.90+ per dollar of revenue
- Operating expenses of $5.8M far exceed $3M revenue indicating unsustainable cost structure for early-stage biotech
- No capital expenditures concerning for pharmaceutical company requiring R&D and infrastructure investment
Key Metrics to Watch
- Gross profit and gross margin trend—must achieve positive contribution margin for sustainability
- Operating cash flow—must turn positive or reach cash burn inflection point within 2 periods
- Cash balance and burn rate—track remaining runway and triggering event for financing needs or runway extension
- Operating expense reduction progress—path to profitability dependent on cost rationalization
Xenetic Biosciences, Inc. (XBIO) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 8.32x current ratio provides a solid financial cushion.
XBIO Profit Margin, ROE & Profitability Analysis
XBIO vs Healthcare Sector: How Xenetic Biosciences, Inc. Compares
How Xenetic Biosciences, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Xenetic Biosciences, Inc. Stock Overvalued? XBIO Valuation Analysis 2026
Based on fundamental analysis, Xenetic Biosciences, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Xenetic Biosciences, Inc. Balance Sheet: XBIO Debt, Cash & Liquidity
XBIO Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Xenetic Biosciences, Inc.'s revenue has grown significantly by 156% over the 5-year period, indicating strong business expansion. The most recent EPS of $-2.57 indicates the company is currently unprofitable.
XBIO Revenue Growth, EPS Growth & YoY Performance
XBIO Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $614.2K | -$436.7K | $-0.28 |
| Q2 2025 | $589.9K | -$688.7K | $-0.45 |
| Q1 2025 | $510.8K | -$903.1K | $-0.59 |
| Q3 2024 | $611.2K | -$436.7K | $-0.28 |
| Q2 2024 | $651.0K | -$1.1M | $-0.69 |
| Q1 2024 | $510.8K | -$856.6K | $-0.56 |
| Q3 2023 | $414.3K | -$804.0K | $-0.56 |
| Q2 2023 | $416.7K | -$1.1M | $-0.69 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Xenetic Biosciences, Inc. Dividends, Buybacks & Capital Allocation
XBIO SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Xenetic Biosciences, Inc. (CIK: 0001534525)
📋 Recent SEC Filings
❓ Frequently Asked Questions about XBIO
What is the AI rating for XBIO?
Xenetic Biosciences, Inc. (XBIO) has an AI rating of STRONG SELL with 85% confidence, based on fundamental analysis of SEC EDGAR filings.
What are XBIO's key strengths?
Claude: Exceptional liquidity with 8.32x current ratio and $7.9M cash position enabling short-term obligations. Minimal leverage with 0.03x debt-to-equity and only $212.8K long-term debt reducing bankruptcy risk.
What are the risks of investing in XBIO?
Claude: Zero gross profit on $3M revenue signals fundamental unit economics failure or one-time revenue event with no scalability. Operating cash burn of -$2.3M annually with only ~$7.9M cash creates 3-4 period runway to insolvency.
What is XBIO's revenue and growth?
Xenetic Biosciences, Inc. reported revenue of $3.0M.
Does XBIO pay dividends?
Xenetic Biosciences, Inc. does not currently pay dividends.
Where can I find XBIO SEC filings?
Official SEC filings for Xenetic Biosciences, Inc. (CIK: 0001534525) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is XBIO's EPS?
Xenetic Biosciences, Inc. has a diluted EPS of $-1.58.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is XBIO a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Xenetic Biosciences, Inc. has a STRONG SELL rating with 85% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is XBIO stock overvalued or undervalued?
Valuation metrics for XBIO: ROE of -36.2% (sector avg: 15%), net margin of -90.1% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy XBIO stock in 2026?
Our dual AI analysis gives Xenetic Biosciences, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is XBIO's free cash flow?
Xenetic Biosciences, Inc.'s operating cash flow is $-2.3M, with capital expenditures of $0.0. FCF margin is -76.8%.
How does XBIO compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -90.1% (avg: 12%), ROE -36.2% (avg: 15%), current ratio 8.32 (avg: 2).